The US Food and Drug Administration revealed that it has approved Johnson&Johnson's tapentadol extended release drug, Nucynta ER in treating moderate-to-severe chronic pain in adults.
The drug, manufactured by the company's Janssen Pharmaceuticals unit, has already been approved by the FDA in 50mg, 75mg and 100mg strengths and is also available in 150mg, 200mg and 250mg strengths.
Some of the common side effects after taking the drug include headache, nausea and dizziness.
Expressing his happiness at the approval, Janssen Pharmaceuticals' Dr Paul Chang said, "In clinical trials, Nucynta ER demonstrated proven efficacy for treating moderate to severe chronic pain. We are pleased with the FDA's decision to approve Nucynta ER as it represents an important new option to help people with chronic pain."